Clinical trials in multiple sclerosis: milestones
نویسندگان
چکیده
منابع مشابه
Age at disability milestones in multiple sclerosis.
Many efforts have been devoted to the description of the prognosis of multiple sclerosis and its possible influential factors in terms of time to reach disability milestones. By contrast, the age at which patients with multiple sclerosis reach these milestones has not yet stirred much interest. We have tested the hypothesis whether the prognosis of multiple sclerosis depends on the current age ...
متن کاملOutcome Measures in Clinical Trials for Multiple Sclerosis
Due to the heterogeneous nature of the disease, it is a challenge to capture disease activity of multiple sclerosis (MS) in a reliable and valid way. Therefore, it can be difficult to assess the true efficacy of interventions in clinical trials. In phase III trials in MS, the traditionally used primary clinical outcome measures are the Expanded Disability Status Scale and the relapse rate. Seco...
متن کاملClinical trials in pediatric multiple sclerosis: overcoming the challenges
To date, none of the formative clinical drug trials in multiple sclerosis (MS) have included children. Just as in other fields in pediatrics, current prescribed therapies are off-label and are based on the results of adult studies. Emerging oral, injectable and intravenous immunotherapies appear to be more efficacious, but simultaneously have more worrisome side effects. In order to optimize th...
متن کاملLessons for clinical trials from natalizumab in multiple sclerosis.
http://bmj.com/cgi/content/full/332/7538/416 Updated information and services can be found at: These include: References http://bmj.com/cgi/content/full/332/7538/416#BIBL This article cites 16 articles, 14 of which can be accessed free at: Rapid responses http://bmj.com/cgi/eletter-submit/332/7538/416 You can respond to this article at: http://bmj.com/cgi/content/full/332/7538/416#responses fre...
متن کاملNumber Needed to Treat in Multiple Sclerosis Clinical Trials
Clinicians are expected to select a therapy based on their appraisal of evidence on benefit-to-risk profiles of therapies. In the management of relapsing-remitting multiple sclerosis (RRMS), evidence is typically expressed in terms of risk (proportion) of event, risk reduction, relative and hazard rate reduction, or relative reduction in the mean number of magnetic resonance imaging lesions. In...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Therapeutic Advances in Neurological Disorders
سال: 2018
ISSN: 1756-2864,1756-2864
DOI: 10.1177/1756286418785499